Immune Thrombocytopenia Clinical Trial
Official title:
A Prospective, One-arm and Open Clinical Study to Assess Efficacy and Safety of Avatrombopag in the Treatment of Pediatric Primary Immune Thrombocytopenia
To evaluate the safety and efficacy of avatrombopag in the treatment of pediatric primary immune thrombocytopenia in patients who have been treated with eltrombopag before and switched to avatrobopag because of poor efficacy, excessive platelet fluctuation or intolerance, or patient preference, economic reasons, and other reasons.
Status | Recruiting |
Enrollment | 60 |
Est. completion date | December 2025 |
Est. primary completion date | December 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 6 Years to 18 Years |
Eligibility | Inclusion Criteria: - Age 6-18 years old (including both ends), male and female; - Diagnosed with primary immune thrombocytopenia (ITP); - Patients who had previously received eltrombopag treatment and then converted to avatrombopag treatment because of ineffectiveness (platelet count < 30×10^9/L after eltrombopag treatment, or platelet count increased less than 2 times of the basic value, or bleeding) or large platelet fluctuation or due to patient preference, economic reasons and other reasons; - Cardiac function of the New York Society of Cardiac Function = 2; - Understand the study procedure and voluntarily sign the informed consent. Exclusion Criteria: - Secondary thrombocytopenia caused by various reasons, such as connective tissue disorders, bone marrow hematopoietic failure disease, myelodysplastic syndrome, malignancy, drugs, inherited thrombocytopenia, common variable immune deficiency, lymphoma, etc.; - Subjects with primary disease of important organs (liver, kidney, heart, etc.), or with immune system diseases; - Subjects who are known to be allergic to avatrombopag or any of its excipients; - Subjects who had used rituximab within the last 3 months; - Subjects who underwent splenectomy within the last 3 months; - Subjects with a history of abnormal platelet aggregation that may affect the reliability of platelet count measurements; - Any medical history or condition that the investigator deems unsuitable for participation in the study. |
Country | Name | City | State |
---|---|---|---|
China | Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College | Tianjin |
Lead Sponsor | Collaborator |
---|---|
Institute of Hematology & Blood Diseases Hospital, China | Henan Cancer Hospital, The Second Affiliated Hospital of Kunming Medical University, Tianjin Children's Hospital, Tianjin Medical University Second Hospital |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Overall efficacy response after AVA treatment within 12 weeks | Overall response rate defined as proportion of subjects with a platelet count = 30 × 10^9/L and at least 2-fold from baseline without bleeding at the meanwhile within 12 weeks after initial administration in absence of rescue therapy. | 12 weeks | |
Secondary | Treatment response-1 | Number of participants achieving a platelet count = 50×10^9/L at week 1,2,4,6,8,12 in absence of rescue therapy. | 12 weeks | |
Secondary | Treatment response-2 | Number of participants achieving a platelet count = 100×10^9/L at week 1,2,4,6,8,12 in absence of rescue therapy. | 12 weeks | |
Secondary | Time to Response | The time required from the start of treatment to the first time a subject's platelet count was greater than or equal to 30×10^9/L and at least a two-fold increase from the baseline platelet count without bleeding in absence of rescue therapy. | 12 weeks | |
Secondary | Persistent response | Persistent response defined as proportion of subjects with a platelet count = 30 × 10^9/L and at least 2-fold from baseline without bleeding for 4 consecutive weeks or more within 12 weeks after initial administration in absence of rescue therapy. | 12 weeks | |
Secondary | Emergency treatment | The proportion of subjects receiving emergency treatment | 12 weeks | |
Secondary | Reduction of concomitant drug | Percentage of patients with reduced doses of concomitant drugs at baseline | 12 weeks | |
Secondary | Number of participants with clinically significant bleeding as assessed using the world health organization (WHO) bleeding scale. | The WHO Bleeding Scale is a measure of bleeding severity with the following grades: grade 0 = no bleeding, grade 1= petechiae, grade 2= mild blood loss, grade 3 = gross blood loss, and grade 4 = debilitating blood loss. | 12 weeks | |
Secondary | Number of participants with clinically significant bleeding as assessed using the bleeding scale for pediatric patients with ITP. | The bleeding scale for pediatric patients with ITP is a measure of bleeding severity with the following grades: Grade 1 (minor) Minor bleeding, few petechiae (=100 total) and/or =5 small bruises (=3 cm in diameter), no mucosal bleeding;Grade 2 (mild) Mild bleeding, many petechiae (>100 total) and/or >5 large bruises (>3 cm in diameter), no mucosal bleeding;Grade 3 (moderate) Moderate bleeding, overt mucosal bleeding, troublesome lifestyle;Grade 4 (severe) Severe bleeding, mucosal bleeding leading to decrease in Hb>2 g/dL or suspected internal hemorrhage; | 12 weeks | |
Secondary | Health-related quality of life survey of subjects(HRQoL)-1 | In all participants ,use ITP-PAQ (ITP Patient Assessment Questionnaire) to assess the HRQoL before and after treatment. | 12 weeks | |
Secondary | Health-related quality of life survey of subjects(HRQoL)-2 | In all participants ,use FACIT-F(functional assessment of chronic illness therapy- fatigue)to assess the HRQoL before and after treatment. | 12 weeks | |
Secondary | Health-related quality of life survey of subjects(HRQoL)-3 | In all participants ,use Kids' ITP tool KIT?to assess the HRQoL before and after treatment. | 12 weeks | |
Secondary | Health-related quality of life survey of subjects(HRQoL)-4 | In all participants ,use Pediatric Quality of Life Inventory PedsQL to assess the HRQoL before and after treatment. | 12 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02287649 -
Polymorphism and Auto-reactive B and T Cells Subsets in Adult's Immune Thrombocytopenia (ITP)
|
N/A | |
Terminated |
NCT02401061 -
PRTX-100-202 Open-Label, Dose Escalation Study in Adult Patients With ITP
|
Phase 1/Phase 2 | |
Completed |
NCT02868099 -
Efficacy and Safety of Romiplostim in Adult Subjects With Persistent or Chronic Immune Thrombocytopenia (ITP)
|
Phase 3 | |
Completed |
NCT02556814 -
Caffeic Acid Combining High-dose Dexamethasone in Management of ITP
|
Phase 4 | |
Completed |
NCT02351622 -
Caffeic Acid Tablets as a Second-line Therapy for ITP
|
Phase 3 | |
Active, not recruiting |
NCT04741139 -
Post IVIG Medication in Children With Immune Thrombocytopenia
|
Phase 1 | |
Not yet recruiting |
NCT05494307 -
The Combination of Terbutaline and Danazol as the Treatment of Corticosteroid-resistant/Relapse Immune Thrombocytopenia
|
Phase 2 | |
Not yet recruiting |
NCT05468866 -
The Expression of Immune Checkpoint CD28 rs1980422-related Single-nucleotide Polymorphisms in the Primary Immune Thrombocytopenia
|
N/A | |
Recruiting |
NCT04993885 -
Avatrombopag in the Treatment of Adult Immune Thrombocytopenia With Autoantibodies
|
Phase 2 | |
Recruiting |
NCT05281068 -
The Combination of Iguratimod and Danazol as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia
|
Phase 2 | |
Not yet recruiting |
NCT05020288 -
A Clinical Trial of the Orelabrutinib in the Management of Refractory ITP
|
Phase 2 | |
Withdrawn |
NCT03965624 -
Efficacy and Safety of Ixazomib and Dexamethasone Refractory Autoimmune Cytopenia
|
Phase 2 | |
Not yet recruiting |
NCT03252457 -
Decitabine Combining Dexamethasone Versus Dexamethasone in Management of ITP
|
Phase 3 | |
Recruiting |
NCT05937828 -
OBS'CEREVANCE: French Cohort of Pediatric Autoimmune Cytopenia
|
||
Completed |
NCT03156452 -
Newly Diagnosed Immune Thrombocytopenia Testing the Standard Steroid Treatment Against Combined Steroid & Mycophenolate
|
Phase 3 | |
Completed |
NCT03164915 -
A Clinical Study to Evaluate the Efficacy and Safety of LIV-GAMMA SN Inj. in Primary Immune Thrombocytopenia (ITP)
|
Phase 3 | |
Recruiting |
NCT02270801 -
Recombinant Human Thrombopoietin (rhTPO) in Management of Immune Thrombocytopenia (ITP) in Pregnancy
|
Phase 3 | |
Completed |
NCT01933035 -
Extended Platelet Parameters as a Means to Differentiate Immune Thrombocytopenia From Hypo-proliferative Thrombocytopenias.
|
N/A | |
Withdrawn |
NCT01976195 -
High-dose Dexamethasone Combining Thalidomide Versus Dexamethasone Mono-therapy for Management of Newly-diagnosed ITP
|
Phase 2 | |
Recruiting |
NCT02821572 -
Role of Fcgamma Receptors in Immune Thrombocytopenia (ITP)
|